Medicare Part D Prescription Claims for Brodalumab: Analysis of Annual Trends for 2017-2019.

The article discusses the side effects of Brodalumab, a monoclonal antibody targeting Interleukin (IL)-17 RA. It mentions that the treatment was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of moderate to severe chronic plaque psoriasis, it is the only biologic agent available for the treatment of psoriasis and mentions that it is associated with an FDA boxed warning due to an increased risk for suicidal ideation and behavior (SIB).